Indo-U.S. Vaccine Action Program Small Research Grant Program

Deadline: 7 May 2019

The Department of Health and Human Services, National Institutes of Health (NIH) is inviting organizations/institutions for Vaccine Action Program (VAP) with an aim to support collaborative vaccine-related research projects that ultimately reduce the burden of infectious diseases of importance in India, the U.S., the South Asian region and globally.

_(Ad)Are You Searching for Latest Grants, New Donors, Sample Proposals, Jobs and How to Apply Resources? fundsforNGOs Premium has all these and more at one place! Learn more.

The program will conduct vaccine-related research through U.S.-Indo collaborations on a variety of infectious diseases, including immunologic characterization.

Priorities

_(Ad)Stop getting irritated with excessing advertisements. View the information you want quickly on a clean, ad-free and exclusive Member Dashboard that offers tools to search for grants, view latest grant opportunities, upcoming deadlines, sample proposals, downloadable ebooks and also organize your favourites! Learn more.

Discovery, demonstration of the proof of principle, development of novel manufacturing processes, evaluation of the safety and efficacy and demonstration of the effectiveness of the use of new and improved vaccines to prevent:
- HIV/AIDS
- Tuberculosis
- Pandemic and interpandemic influenza
- Dengue and Dengue Hemorrhagic Fever (DHF)
- Malaria
- Enteric diseases
Discovery and/or development of vaccine adjuvants promoting mucosal or systemic responses; analysis of their mechanism of action; optimization of vaccine adjuvants to increase efficacy while reducing reactogenicity; development of in vitro assays for evaluating adjuvanticity and/or reactogenicity; identification of correlates of adjuvanticity;
Characterization of local and/or systemic immune responses and regulatory mechanisms in infants, compared to older children or adults, to vaccines or natural exposure/illness due to infectious diseases;
Mechanisms of systemic or mucosal immune response across the lifespan to infection or vaccination, including characterization of mucosal vaccine immune responses, and correlates/surrogates of mucosal immune responses;
New manufacturing and vaccine delivery technology;
Effectiveness of the introduction of new and improved vaccines into public health immunization programs;
Epidemiology of infectious disease in the human population.